Strategic Expansion ITM is expanding its global footprint with a new 7,000 square meter facility in Germany, dramatically boosting Lutetium-177 production capacity. This expansion signals a growing demand for radiopharmaceuticals and presents opportunities to partner on supply agreements, contract manufacturing, and regional clinical trials across Europe.

Phase 3 momentum A broad precision oncology pipeline includes multiple Phase 3 studies (COMPETE and ITM-11), with positive endpoints and post-hoc analyses presented at major conferences. This indicates a robust value proposition for oncology prescribers, payers, and distribution partners seeking late-stage assets and strategic collaborations in neuroendocrine and GEP-NET indications.

Clinical partnerships ITM’s focus on high-quality radioisotopes combined with targeting molecules creates opportunities for collaborations with hospitals, research centers, and pharma partners to co-develop diagnostics and therapeutics, expand patient access, and accelerate market readiness in radiopharmacy.

Global supply network With an established global network and a mission to ensure reliable production and supply, ITM offers capabilities for supply chain partnerships, including logistics optimization, regulatory compliance support, and regional distribution arrangements across Europe and beyond.

Recognition and credibility Industry awards and participation in high-profile conferences (ESMO, ENETS, SNMMI) reinforce ITM’s leadership in dosimetry and radiopharmaceuticals, enhancing credibility with potential customers, collaborators, and funding partners seeking proven expertise and sophisticated manufacturing capabilities.